| scholarly article | Q13442814 |
| P50 | author | Katherine A. High | Q41502889 |
| P2093 | author name string | Katherine A High | |
| P2860 | cites work | The gene therapy journey for hemophilia: are we there yet? | Q26823818 |
| Genotype analysis identifies the cause of the "royal disease" | Q28260921 | ||
| Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
| Establishing haemophilia care in developing countries: using data to overcome the barrier of pessimism | Q30594692 | ||
| The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion | Q30745198 | ||
| AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. | Q34168942 | ||
| Molecular cloning of the gene for human anti-haemophilic factor IX. | Q34253608 | ||
| Canine hemophilia B resulting from a point mutation with unusual consequences | Q34326780 | ||
| Haemophilia B: database of point mutations and short additions and deletions--eighth edition | Q34646217 | ||
| X-linked thrombophilia with a mutant factor IX (factor IX Padua). | Q35008970 | ||
| Molecular defect in factor IXHilo, a hemophilia Bm variant: Arg----Gln at the carboxyterminal cleavage site of the activation peptide. | Q35552151 | ||
| Adenovirus-associated virus vector-mediated gene transfer in hemophilia B | Q35691659 | ||
| Haemophilia B: database of point mutations and short additions and deletions | Q35850420 | ||
| Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer | Q35876970 | ||
| Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo | Q35914452 | ||
| Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus | Q36159178 | ||
| The tragic history of AIDS in the hemophilia population, 1982-1984. | Q36593789 | ||
| Immune responses to AAV vectors: overcoming barriers to successful gene therapy | Q36983740 | ||
| A mutation in the propeptide of Factor IX leads to warfarin sensitivity by a novel mechanism | Q37360472 | ||
| Successful expression of human factor IX following repeat administration of adenoviral vector in mice. | Q37685172 | ||
| Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges | Q37866086 | ||
| Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion | Q38520320 | ||
| Efficient transfection of primary cells in a canine hemophilia B model using adenovirus-polylysine-DNA complexes | Q41484655 | ||
| Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. | Q41722852 | ||
| Purification and some characteristics of the coagulation factor IX from human plasma | Q42551302 | ||
| Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets | Q42613058 | ||
| Cell phones and landlines: the impact of gene therapy on the cost and availability of treatment for hemophilia | Q42933613 | ||
| Functional consequences of an arginine180 to glutamine mutation in factor IX Hilo | Q43631516 | ||
| Molecular cloning of a cDNA encoding canine factor IX. | Q43812882 | ||
| Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial | Q44328165 | ||
| Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors | Q45299117 | ||
| Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
| Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes | Q45865401 | ||
| Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A | Q45868121 | ||
| Effects of HIV infection on age and cause of death for persons with hemophilia A in the United States | Q45876110 | ||
| Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. | Q45877779 | ||
| Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males | Q45881920 | ||
| Factor IX New London: substitution of proline for glutamine at position 50 causes severe hemophilia B. | Q45883230 | ||
| A coagulation factor IX-deficient mouse model for human hemophilia B. | Q45884173 | ||
| Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation | Q45884343 | ||
| Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
| Characterization of the human factor VIII gene | Q48385931 | ||
| Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group | Q72036552 | ||
| PURIFICATION OF ANTIHEMOPHILIC FACTOR (FACTOR VIII) BY AMINO ACID PRECIPITATION | Q76851315 | ||
| Gene therapy for haemophilia | Q80702723 | ||
| P433 | issue | 11 | |
| P921 | main subject | hemophilia | Q134003 |
| gene therapy | Q213901 | ||
| P304 | page(s) | 915-922 | |
| P577 | publication date | 2014-11-01 | |
| P1433 | published in | Human Gene Therapy | Q15757580 |
| P1476 | title | Gene therapy for hemophilia: the clot thickens | |
| P478 | volume | 25 |
| Q37463554 | Clinical and imaging analysis of subclinical hemophilia combined with coxarthrosis: case report and literature review |
| Q91652406 | Defining the Optimal FVIII Transgene for Placental Cell-Based Gene Therapy to Treat Hemophilia A |
| Q37717907 | Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors |
Search more.